IDgene Pharmaceuticals Ltd.
This article was originally published in Start Up
IDgene Pharmaceuticals Ltd. is collecting genetic and clinical data from 2.5 million Israeli Ashkenzi Jews to identify the genetic roots of common diseases and illuminate their underlying biochemical pathways. The company will provide pharmaceutical partners with validated targets and in the future, pursue some drug development on its own.
You may also be interested in...
CombinatoRx's platform screens combinations of known drugs to find pairs that could deliver a one-two punch to diseases such as cancer and rheumatoid arthritis.
Paths to commercialization are uncertain in nutrigenomics, an emerging science which seeks to identify gene-food interactions that differ among subpopulations and between individuals and to personalize diets to prevent disease.
NutraGenomics Inc. is using a systems approach to identify diet-responsive genes and SNPs involved in chronic diseases such as Type 2 diabetes, obesity, atherosclerosis, and certain cancers, using proprietary mouse models to examine dietary effects on genes, proteins, transcription, and metabolism.